Meeting
2020 Gastrointestinal Cancers Symposium
Trifluridine/tipiracil in combination with oxaliplatin and either bevacizumab or nivolumab: Results of the expansion part of a phase I study in patients with metastatic colorectal cancer.
Authors
Roberto Bordonaro
Medical Oncology, National Specialist Hospital Garibaldi, Catania, Italy
Roberto Bordonaro , Aitana Calvo , Alessandra Auriemma , Antoine Hollebecque , Gabor Rubovszky , Mark P. Saunders , Zsuzsanna Papai , Gerald W. Prager , Alexander Stein , Thierry Andre , Guillem Argiles , Antonio Cubillo , Laetitia Dahan , Julien Edeline , Catherine Leger , Nadia Amellal , Valerie Cattan , Josep Tabernero
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Anal and Colorectal Cancer
Track
Colorectal Cancer,Anal Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT02848443
Citation
J Clin Oncol 38, 2020 (suppl 4; abstr 140)
Abstract #
140
Poster Bd #
G4
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
A phase I clinical trial of riluzole in combination with mFOLFOX6 and bevacizumab in treating patients with metastatic colorectal cancer.
First Author: Chunjie Li
Poster
2019 Gastrointestinal Cancers Symposium
A phase I study of TAS-102 in combination with oxaliplatin (TAS-OX) for refractory metastatic colorectal cancer (mCRC).
First Author: Michael Cecchini
Poster
2018 ASCO Annual Meeting
A real-world experience of nivolumab in advanced malignant mesothelioma (MM).
First Author: Hussein Hamad
Poster
2017 ASCO Annual Meeting
A phase I dose-escalation of trifluridine/tipiracil in combination with oxaliplatin in metastatic colorectal cancer.
First Author: Antoine Hollebecque